Soleno Therapeutics Inc SEC Filings

Soleno Therapeutics insider updates equity holdings after RSU vesting

A Soleno Therapeutics officer, the Chief Commercial Officer, reported an automatic share withholding related to restricted stock units. On December 15, 2025, the company withheld 1,922 shares of common stock at $49.95 per share to cover the reporting person's tax obligations when RSUs vested on that date. After this tax withholding, the officer beneficially owned 43,429 shares of common stock, some of which are RSUs, with each RSU representing a contingent right to receive one share subject to its vesting schedule and conditions.

Soleno Therapeutics Inc. reported an insider equity transaction by its Chief Financial Officer, James Mackaness. On December 15, 2025, 2,013 shares of common stock were disposed of at a price of $49.95 per share. The shares were withheld by the company to cover the officer’s tax obligations arising from the vesting and settlement of restricted stock units (RSUs).

Following this tax withholding transaction, the reporting person beneficially owns 103,163 shares of Soleno Therapeutics common stock. A portion of this balance consists of RSUs, each representing a contingent right to receive one share of common stock, subject to applicable vesting schedules and conditions.

Soleno Therapeutics senior vice president of clinical development reported a routine share withholding transaction related to equity compensation. On December 15, 2025, the officer had 812 shares of common stock withheld by the company at a price of $49.95 per share to cover tax obligations arising from the vesting and settlement of restricted stock units (RSUs). After this tax withholding, the officer beneficially owned 36,005 shares of Soleno Therapeutics common stock. Some of these holdings consist of RSUs, each representing a contingent right to receive one share of common stock, subject to vesting schedules and conditions.

Soleno Therapeutics officer and Senior Vice President of Regulatory Affairs reported an automatic share withholding related to vested restricted stock units (RSUs). On December 15, 2025, 904 shares of common stock were withheld by the company to cover the reporting person’s tax obligations upon RSU settlement at a price of $49.95 per share. After this tax withholding transaction, the insider beneficially owned 12,302 shares of Soleno Therapeutics common stock. Certain of the remaining holdings consist of RSUs, each representing a contingent right to receive one share of common stock, subject to their vesting schedules and conditions.

Soleno Therapeutics chief executive officer and director Anish Bhatnagar reported equity transactions in company stock. On December 15, 2025, 7,620 shares of common stock were withheld by the company at a price of $49.95 to cover tax obligations related to vested restricted stock units. On the same date, he transferred 100,000 shares of common stock as a gift, for no consideration, to two family trusts for the benefit of his descendants.

After these transactions, Bhatnagar beneficially owned 469,456 shares of Soleno Therapeutics common stock, some of which are in the form of restricted stock units, each representing a contingent right to receive one share subject to vesting conditions. He reports beneficial ownership of the gifted shares only to the extent of any pecuniary interest and disclaims beneficial ownership of the shares held by the trusts.

Soleno Therapeutics (SLNO) reported an equity award and option activity for its Chief Business Officer. On 11/17/2025, the officer acquired 14,286 restricted stock units (RSUs)$0, all held directly after the transaction. Each RSU represents the right to receive one share of common stock.

One-half of these RSUs will vest on November 17, 2026, with one third of the remaining units vesting on each one-year anniversary after that, as long as the officer continues as a service provider. The filing also shows an employee stock option covering 64,286 shares of common stock at an exercise price of $47.25 per share, expiring on 11/17/2035. One-fourth of the option shares will vest on November 17, 2026, and one forty-eighth of the shares will vest monthly thereafter, subject to continued service.

Soleno Therapeutics Inc. (SLNO) disclosed a new insider reporting status for its Chief Business Officer through a Form 3 filing. This form identifies the individual as an officer of the company and confirms that the filing is made by a single reporting person. The filing states in the remarks that no securities are beneficially owned, meaning the officer reports holding no Soleno shares or derivative securities as of the event date.

Soleno Therapeutics (SLNO) reported an insider ownership update via a Form 3. The filing identifies the reporting person as an Officer (Chief Development Officer) and states that no securities are beneficially owned as of the event date 11/10/2025. The document serves as an initial statement of ownership under Section 16 and was signed by an attorney-in-fact.

Soleno Therapeutics entered an accelerated share repurchase with Jefferies to repurchase $100.0 million of common stock. The Company prepaid $100.0 million and received an initial delivery of 1,511,553 shares, with any remaining shares expected by the end of its first fiscal quarter of 2026. The final share count will be based on the stock’s volume‑weighted average price during the program, less an agreed discount, with settlement adjustments that could require either party to deliver additional shares or, in Soleno’s case, make a cash payment.

In connection with the ASR, Soleno amended its Oxford Finance loan agreement to permit the repurchase and to modify previously committed capacity. Lenders are no longer obligated to fund the $25.0 million Term C Loans or $25.0 million Term D Loans. After the amendment, the remaining $100.0 million of loans is uncommitted and may be made available only upon mutual agreement.